scholarly journals Brief Report: Large-scale analysis of tumor necrosis factor α levels in systemic lupus erythematosus

2012 ◽  
Vol 64 (9) ◽  
pp. 2947-2952 ◽  
Author(s):  
Corinna E. Weckerle ◽  
Dorothy Mangale ◽  
Beverly S. Franek ◽  
Jennifer A. Kelly ◽  
Marissa Kumabe ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Tumor Necrosis ◽  
Large Scale ◽  
Tumor Necrosis Factor Α ◽  
Scale Analysis ◽  
Systemic Lupus ◽  
Large Scale Analysis ◽  
Factor Α ◽  
Necrosis Factor

scholarly journals Tumor Necrosis Factor-α Antagonist Etanercept Decreases Blood Pressure and Protects the Kidney in a Mouse Model of Systemic Lupus Erythematosus

Hypertension ◽  
2010 ◽  
Vol 56 (4) ◽  
pp. 643-649 ◽  
Author(s):  
Marcia Venegas-Pont ◽  
Michaele B. Manigrasso ◽  
Samira C. Grifoni ◽  
Babbette B. LaMarca ◽  
Christine Maric ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Blood Pressure ◽  
Tumor Necrosis Factor ◽  
Mouse Model ◽  
Lupus Erythematosus ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Systemic Lupus ◽  
Factor Α ◽  
Necrosis Factor

Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor α protective?

2004 ◽  
Vol 33 (6) ◽  
pp. 404-413 ◽  
Author(s):  
Diana Gómez ◽  
Paula A. Correa ◽  
Luis Miguel Gómez ◽  
José Cadena ◽  
José F. Molina ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Tumor Necrosis Factor ◽  
Lupus Erythematosus ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Th2 Cytokines ◽  
Systemic Lupus ◽  
Factor Α ◽  
Necrosis Factor

scholarly journals Adiponectin Deregulation in Systemic Autoimmune Rheumatic Diseases

2021 ◽  
Vol 22 (8) ◽  
pp. 4095
Author(s):  
Neža Brezovec ◽  
Katja Perdan-Pirkmajer ◽  
Saša Čučnik ◽  
Snežna Sodin-Šemrl ◽  
John Varga ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Tumor Necrosis Factor ◽  
Lupus Erythematosus ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Systemic Lupus ◽  
Autoimmune Rheumatic Diseases ◽  
Factor Α ◽  
Necrosis Factor

Deregulation of adiponectin is found in systemic autoimmune rheumatic diseases (SARDs). Its expression is downregulated by various inflammatory mediators, but paradoxically, elevated serum levels are present in SARDs with high inflammatory components, such as rheumatoid arthritis and systemic lupus erythematosus. Circulating adiponectin is positively associated with radiographic progression in rheumatoid arthritis as well as with cardiovascular risks and lupus nephritis in systemic lupus erythematosus. However, in SARDs with less prominent inflammation, such as systemic sclerosis, adiponectin levels are low and correlate negatively with disease activity. Regulators of adiponectin gene expression (PPAR-γ, Id3, ATF3, and SIRT1) and inflammatory cytokines (interleukin 6 and tumor necrosis factor α) are differentially expressed in SARDs and could therefore influence total adiponectin levels. In addition, anti-inflammatory therapy could also have an impact, as tocilizumab treatment is associated with increased serum adiponectin. However, anti-tumor necrosis factor α treatment does not seem to affect its levels. Our review provides an overview of studies on adiponectin levels in the bloodstream and other biological samples from SARD patients and presents some possible explanations why adiponectin is deregulated in the context of therapy and gene regulation.

Sign in / Sign up

Export Citation Format

Share Document